Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post

Aarti Pharmalabs Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹888.96Undervalued by 10.29%vs CMP ₹806.00

P/E (33.7) × ROE (14.5%) × BV (₹226.00) × DY (0.62%)

₹426.11Overvalued by 47.13%vs CMP ₹806.00
MoS: -89.2% (Negative)Confidence: 63/100 (Moderate)Models: 1 Under, 8 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹911.3123%Under (+13.1%)
Graham NumberEarnings₹346.2714%Over (-57%)
Earnings PowerEarnings₹132.2111%Over (-83.6%)
DCFCash Flow₹216.8014%Over (-73.1%)
Net Asset ValueAssets₹226.867%Over (-71.9%)
EV/EBITDAEnterprise₹537.899%Over (-33.3%)
Earnings YieldEarnings₹235.807%Over (-70.7%)
ROCE CapitalReturns₹286.447%Over (-64.5%)
Revenue MultipleRevenue₹234.526%Over (-70.9%)
Consensus (9 models)₹426.11100%Overvalued
Key Drivers: Wide model spread (₹132–₹911) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 2.5%

*Investments are subject to market risks

Analyst Summary

Aarti Pharmalabs Ltd operates in the Pharmaceuticals segment, NSE: AARTIPHARM | BSE: 543748, current market price is ₹806.00, market cap is 7,269 Cr.. At a glance, stock P/E is 33.7, ROE is 14.5 %, ROCE is 17.4 %, book value is 226, dividend yield is 0.62 %. The latest intrinsic value estimate is ₹426.11, around 47.1% below the current price, so expectations may already be running ahead of this modelled fair value. On operating trend, latest reported sales are about ₹2,115 Cr versus the prior period change of 14.1%, while latest net profit is about ₹272 Cr with a prior-period change of 25.3%. The 52-week range shown on this page is 972/584, which helps frame where the current quote sits within its recent trading band. Business context: About the Company - Qualitative AnalysisAarti Pharmalabs Ltd. is a Public Limited Listed company incorporated on 22/11/2019 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L241…

This summary is generated from the stock page data available for Aarti Pharmalabs Ltd: Intrinsic Value & Share Price Analysis and is refreshed automatically when the underlying metrics change.

Investment Snapshot

62
Aarti Pharmalabs Ltd scores 62/100 (Average)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health77/100 · Strong
ROCE 17.4% GoodROE 14.5% GoodD/E 0.24 Low debtInterest Coverage 0.0x RiskyProfitable 4/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.33% (6mo) Slight increasePromoter holding at 43.1% Stable
Earnings Quality65/100 · Strong
OPM expanding (18% → 22%) Improving
Quarterly Momentum25/100 · Weak
Revenue (4Q): -12% YoY DecliningProfit (4Q): -14% YoY Declining
Industry Rank75/100 · Strong
P/E 33.7 vs industry 60.2 Cheaper than peersROCE 17.4% vs industry 16.5% Average3Y sales CAGR: 21% High growth

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: May 5, 2026, 2:06 am

Market Cap 7,269 Cr.
Current Price 806
Intrinsic Value₹426.11
High / Low 972/584
Stock P/E33.7
Book Value 226
Dividend Yield0.62 %
ROCE17.4 %
ROE14.5 %
Face Value 5.00
PEG Ratio13.40

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Aarti Pharmalabs Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Aarti Pharmalabs Ltd 7,269 Cr. 806 972/58433.7 2260.62 %17.4 %14.5 % 5.00
Sanofi India Ltd 7,828 Cr. 3,400 6,410/3,15123.8 3262.21 %57.5 %43.0 % 10.0
Shilpa Medicare Ltd 8,184 Cr. 419 502/26046.3 1250.12 %7.82 %4.21 % 1.00
Blue Jet Healthcare Ltd 8,273 Cr. 476 1,028/32528.2 72.40.25 %39.8 %30.2 % 2.00
FDC Ltd 6,050 Cr. 372 528/31326.1 1491.34 %15.9 %11.8 % 1.00
Industry Average20,594.11 Cr1,138.8760.16202.220.35%16.48%15.27%6.10

All Competitor Stocks of Aarti Pharmalabs Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 472485458440449506555458538564386418432
Expenses 385405373352353388459364409418293344330
Operating Profit 868085889611896941291469374102
OPM % 18%16%19%20%21%23%17%20%24%26%24%18%24%
Other Income 010112245-2202
Interest 5644455610771113
Depreciation 16161718191920212323232529
Profit before tax 6559646774967472101115653963
Tax % 27%27%26%23%29%32%25%24%26%23%24%28%24%
Net Profit 48434752536555557488502848
EPS in Rs 5.264.735.205.725.827.206.126.038.169.755.463.085.29

Last Updated: March 3, 2026, 1:18 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 26, 2026, 1:41 pm

MetricMar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales -01,2001,9451,8532,1151,801
Expenses -09931,6031,4671,6511,385
Operating Profit -0207342386464415
OPM % 17%18%21%22%23%
Other Income -0325102
Interest -01221172737
Depreciation -04263738799
Profit before tax -0155261300361282
Tax % 21%26%28%24%
Net Profit -0122193217272214
EPS in Rs 21.3523.9330.0523.58
Dividend Payout % -0%9%13%17%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2022-20232023-20242024-2025
YoY Net Profit Growth (%)58.20%12.44%25.35%
Change in YoY Net Profit Growth (%)0.00%-45.76%12.91%

Aarti Pharmalabs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:%
5 Years:%
3 Years:21%
TTM:0%
Compounded Profit Growth
10 Years:%
5 Years:%
3 Years:31%
TTM:18%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:%
1 Year:28%
Return on Equity
10 Years:%
5 Years:%
3 Years:14%
Last Year:15%

Last Updated: September 5, 2025, 2:01 pm

Balance Sheet

Last Updated: December 4, 2025, 2:16 am

MonthMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 0.250.2545454545
Reserves -01,3861,5131,7121,9452,001
Borrowings 0341215285413659
Other Liabilities 0312470540503561
Total Liabilities 02,0402,2442,5822,9063,266
Fixed Assets 07829261,0331,1371,515
CWIP 0187102137374160
Investments 0328710777187
Other Assets 01,0381,1301,3051,3191,403
Total Assets 02,0402,2442,5822,9063,266

Reserves and Borrowings Chart

Cash Flow

MonthMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 0-44250216332
Cash from Investing Activity + 0-139-158-215-414
Cash from Financing Activity + 0260-1631065
Net Cash Flow 078-7112-17
Free Cash Flow 0-18513018-112
CFO/OP -11%91%71%85%

Free Cash Flow

MonthMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow0.00-134.00127.00101.0051.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1158410299
Inventory Days 272188230190
Days Payable 12310613590
Cash Conversion Cycle 264166197200
Working Capital Days 11194110105
ROCE %19%16%17%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 45.98%45.98%46.30%46.46%46.46%46.46%46.10%44.65%44.29%43.72%42.88%43.10%
FIIs 7.69%7.43%8.45%8.17%8.33%7.07%7.38%8.64%7.36%7.34%8.02%7.69%
DIIs 13.68%10.65%10.51%9.91%9.97%11.47%11.35%10.36%7.53%7.80%6.95%7.66%
Government 0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public 32.64%35.92%34.73%35.45%35.24%35.00%35.17%36.33%40.81%41.12%42.12%41.54%
No. of Shareholders 2,76,6642,58,2392,26,2862,15,7962,04,1221,89,0121,85,4361,85,1111,96,3141,87,0391,90,6551,84,489

Shareholding Pattern Chart

No. of Shareholders

Aarti Pharmalabs Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
UTI Healthcare Fund 128,133 0.84 9.2786,3632026-03-12 05:40:3148.37%
ICICI Prudential Exports and Services Fund 100,000 0.53 7.24N/AN/AN/A
ICICI Prudential Childrens Fund 93,759 0.48 6.79100,0002026-01-26 05:56:47-6.24%
Taurus Flexi Cap Fund 72,058 1.51 5.2159,0582025-12-15 01:09:1522.01%
HDFC Large and Mid Cap Fund 67,500 0.02 4.89N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22
FaceValue 5.005.005.0010.00
Basic EPS (Rs.) 30.0623.9321.3513.49
Diluted EPS (Rs.) 30.0423.9321.3513.49
Cash EPS (Rs.) 39.6432.0128.2536.08
Book Value[Excl.RevalReserv]/Share (Rs.) 219.55193.88171.97304.30
Book Value[Incl.RevalReserv]/Share (Rs.) 219.55193.88171.97304.30
Revenue From Operations / Share (Rs.) 233.36204.42214.64263.36
PBDIT / Share (Rs.) 52.3543.1438.0045.97
PBIT / Share (Rs.) 42.7635.0631.1036.73
PBT / Share (Rs.) 39.8033.1628.7734.10
Net Profit / Share (Rs.) 30.0623.9321.3526.83
NP After MI And SOA / Share (Rs.) 30.0623.9321.3526.83
PBDIT Margin (%) 22.4321.1017.7017.45
PBIT Margin (%) 18.3217.1414.4813.94
PBT Margin (%) 17.0516.2113.4012.94
Net Profit Margin (%) 12.8711.709.9410.18
NP After MI And SOA Margin (%) 12.8711.709.9410.18
Return on Networth / Equity (%) 13.6812.3412.418.81
Return on Capital Employeed (%) 17.2316.8317.1911.46
Return On Assets (%) 9.378.408.675.99
Long Term Debt / Equity (X) 0.050.000.000.00
Total Debt / Equity (X) 0.190.150.130.24
Asset Turnover Ratio (%) 0.770.760.750.00
Current Ratio (X) 2.011.941.951.77
Quick Ratio (X) 1.121.010.930.95
Inventory Turnover Ratio (X) 3.441.381.780.00
Dividend Payout Ratio (NP) (%) 11.648.3510.042.02
Dividend Payout Ratio (CP) (%) 8.826.247.591.50
Earning Retention Ratio (%) 88.3691.6589.9697.98
Cash Earning Retention Ratio (%) 91.1893.7692.4198.50
Interest Coverage Ratio (X) 17.6422.7116.3617.52
Interest Coverage Ratio (Post Tax) (X) 11.1313.6010.1911.22
Enterprise Value (Cr.) 7172.164182.272678.010.00
EV / Net Operating Revenue (X) 3.392.261.380.00
EV / EBITDA (X) 15.1210.707.780.00
MarketCap / Net Operating Revenue (X) 3.212.131.280.00
Retention Ratios (%) 88.3591.6489.9597.97
Price / BV (X) 3.412.241.600.00
Price / Net Operating Revenue (X) 3.212.131.280.00
EarningsYield 0.040.050.070.00

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Aarti Pharmalabs Ltd. is a Public Limited Listed company incorporated on 22/11/2019 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2019PLC110964 and registration number is 110964. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1771.35 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsPlot No 22/C/1 & 22/C/2, Vapi Gujarat 396195Contact not found
Management
NamePosition Held
Mr. Chandrakant Vallabhaji GogriChairman Emeritus
Mr. Rashesh C GogriChairman & Non-Exe.Director
Mrs. Hetal Gogri GalaVice Chairperson & M.D
Mr. Narendra J SalviManaging Director
Mr. Rajendra V GogriNon Executive Director
Mr. Parimal H DesaiNon Executive Director
Ms. Nehal GarewalNon Executive Director
Mr. Bhavesh R VoraIndependent Director
Mrs. Jeenal K SavlaIndependent Director
Mrs. Rupal A VoraIndependent Director
Mr. Vilas Gajanan GaikarIndependent Director
Dr. Vinay G NayakIndependent Director
Mr. Pradeep H ThakurIndependent Director

FAQ

What is the intrinsic value of Aarti Pharmalabs Ltd and is it undervalued?

As of 10 May 2026, Aarti Pharmalabs Ltd's intrinsic value is ₹426.11, which is 47.13% lower than the current market price of ₹806.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (14.5 %), book value (₹226), dividend yield (0.62 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Aarti Pharmalabs Ltd?

Aarti Pharmalabs Ltd is trading at ₹806.00 as of 10 May 2026, with a FY2026-2027 high of ₹972 and low of ₹584. The stock is currently in the middle of its 52-week range. Market cap stands at ₹7,269 Cr..

How does Aarti Pharmalabs Ltd's P/E ratio compare to its industry?

Aarti Pharmalabs Ltd has a P/E ratio of 33.7, which is below the industry average of 60.16. This is broadly in line with or below the industry average.

Is Aarti Pharmalabs Ltd financially healthy?

Key indicators for Aarti Pharmalabs Ltd: ROCE of 17.4 % indicates efficient capital utilization. Dividend yield is 0.62 %.

Is Aarti Pharmalabs Ltd profitable and how is the profit trend?

Aarti Pharmalabs Ltd reported a net profit of ₹272 Cr in Mar 2025 on revenue of ₹2,115 Cr. Compared to ₹122 Cr in Mar 2022, the net profit shows an improving trend.

Does Aarti Pharmalabs Ltd pay dividends?

Aarti Pharmalabs Ltd has a dividend yield of 0.62 % at the current price of ₹806.00. The company pays dividends, though the yield is modest.

Last Updated: May 5, 2026, 2:06 am
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 543748 | NSE: AARTIPHARM
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Aarti Pharmalabs Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports